Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

2017; Wiley; Volume: 6; Issue: 10 Linguagem: Inglês

10.1161/jaha.116.005367

ISSN

2047-9980

Autores

Peter P. Tóth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I Cheng, Ian Bridges, Gavin Worth, Ricardo Dent, Carol Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S.G. Stroes,

Tópico(s)

Pharmaceutical Practices and Patient Outcomes

Resumo

The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low-density lipoprotein cholesterol (LDL-C) when added to statin therapy in patients who need additional LDL-C reduction.

Referência(s)